DGX

Quest Diagnostics
D

DGX

Arincen63/100B
255.59
USD
0.87
(0.34%)
Pre Open
Fair value202.30Plus+26%77Price 255.59264
Q4 FY2026 · Earnings report
EPS estimate 2.68Revenue estimate 3.04B
OverviewFinancialsForecastEarningsDividendsCompany

Quest Diagnostics P/E ratio

Quest Diagnostics's P/E ratio is 25.11: its share price of 255.59 over its earnings per share of 10.18 over the last twelve months.

Today
25.11
Forward P/E, next 12 months
21.51
PEG ratio
2.26
Median, 5 years
19.87
Low, 5 years
7.61
High, 5 years
25.96

P/E ratio = price ÷ EPS (last 12 months) = 255.59 ÷ 10.18 = 25.11

Each day's closing price over the earnings per share of the last four quarters reported by that day (basic EPS, adjusted for splits). The P/E moves with the price every day and with the earnings at each report.

The forward P/E divides the price by the analysts' average EPS estimate for the next twelve months: the fiscal year in progress for the months left in it, the next one for the rest. For past days it uses each year's latest estimate, as the estimates of the time were not recorded (we keep a daily copy from November 2026), so the past line reads the price against the earnings expected by the time each year was reported.

Is Quest Diagnostics's P/E high compared with its own history?

Quest Diagnostics's P/E of 25.1 is near the top of its 5-year range (7.6 to 26.0, median 19.9). It is within 5% of its 5-year high. Analysts expect faster growth than in recent years, which can explain part of the high P/E.

Is the price fair? See the whole check

A P/E is compared with the stock's own last five years, not with other companies. Why the market pays more or less (news, rates, the sector) is not in these figures.

P/E ratio by year and by quarter

Fiscal yearPeriod endingP/E ratioForward P/EMarket capNet income
FY2027 · Estimate31 Dec 202721.34———
FY2026 · Estimate31 Dec 202622.60———
Today25.1121.5128.21B1.17B
FY202531 Dec 202518.4115.3419.26B1.05B
FY202431 Dec 202418.1815.3716.75B921.00M
FY202331 Dec 202317.0115.5015.44B908.00M
FY202231 Dec 202217.8817.9518.15B1.02B
FY202131 Dec 202110.4017.5721.63B2.08B
FY202031 Dec 202010.659.8915.97B1.50B
FY201931 Dec 201915.799.8914.31B906.00M
FY201831 Dec 201814.3715.5611.32B788.00M
FY201731 Dec 201716.3815.5613.49B824.00M
FY201631 Dec 201618.4916.2812.87B696.00M
FY201531 Dec 201513.6013.9510.24B753.00M
FY201431 Dec 201416.4314.069.72B592.00M
FY201331 Dec 20139.2213.328.14B883.00M
FY201231 Dec 201215.6112.959.24B592.10M
FY201131 Dec 201118.2213.419.21B505.70M
FY201031 Dec 201012.5312.949.48B757.00M
FY200931 Dec 200914.6515.6811.22B766.20M
FY200831 Dec 200817.3414.8310.09B581.50M
FY200731 Dec 200730.0717.9910.22B339.94M
FY200631 Dec 200617.8018.0410.44B586.42M
FY200531 Dec 200519.0219.2110.39B546.28M
FY200431 Dec 200419.5017.709.74B499.20M
FY200331 Dec 200317.3315.367.57B436.72M
FY200231 Dec 200217.0414.825.49B322.15M
FY200131 Dec 200141.2225.616.69B162.30M
FY200031 Dec 200060.5645.036.36B104.95M
FY199931 Dec 1999—15.921.04B-1.30M
FY199831 Dec 199819.7819.35532.02M26.90M
FY199731 Dec 1997—24.11488.86M-22.30M
FY199631 Dec 1996—32.87443.97M-625.96M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters. A forecast year's P/E is today's price over the analysts' EPS estimate for that year.

See also:Market cap,P/S ratio,Dividend yield,ROE (return on equity),Debt to equity,Current ratio,All ratios

Common questions about Quest Diagnostics's P/E ratio

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.